Symbols / ENGN Stock $7.20 -9.89% enGene Therapeutics Inc.
ENGN (Stock) Chart
Stock Fundamentals
|
|
|
|
|
|
About
enGene Therapeutics Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company in Canada. The company develops genetic medicines to help patients suffering from bladder cancer. Its lead product candidate is detalimogene voraplasmid, a monotherapy for the treatment of non-muscle invasive bladder cancer (NMIBC). Its pipeline includes LEGEND, which is in Phase 2. The company was formerly known as enGene Holdings Inc. and changed its name to enGene Therapeutics Inc. in April 2026. enGene Therapeutics Inc. is based in Montreal, Canada.
Ratings
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2026-04-13 | init | WBB Securities | — → Buy | $22 |
| 2026-03-11 | main | Oppenheimer | Outperform → Outperform | $30 |
| 2026-03-09 | reit | HC Wainwright & Co. | Buy → Buy | $25 |
| 2025-11-12 | main | Morgan Stanley | Overweight → Overweight | $19 |
| 2025-11-12 | reit | Oppenheimer | Outperform → Outperform | $33 |
| 2025-11-12 | main | UBS | Neutral → Neutral | $10 |
| 2025-11-12 | main | Citizens | Market Outperform → Market Outperform | $21 |
| 2025-09-12 | main | Morgan Stanley | Overweight → Overweight | $18 |
| 2025-09-12 | reit | HC Wainwright & Co. | Buy → Buy | $25 |
| 2025-09-08 | reit | HC Wainwright & Co. | Buy → Buy | $25 |
| 2025-04-29 | reit | JMP Securities | Market Outperform → Market Outperform | $18 |
| 2025-03-11 | main | Morgan Stanley | Overweight → Overweight | $34 |
| 2025-03-11 | reit | HC Wainwright & Co. | Buy → Buy | $25 |
| 2025-02-18 | init | Piper Sandler | — → Overweight | $26 |
| 2025-02-14 | down | UBS | Buy → Neutral | $7 |
| 2024-12-23 | reit | JMP Securities | Market Outperform → Market Outperform | $18 |
| 2024-12-23 | init | HC Wainwright & Co. | — → Buy | $25 |
| 2024-12-06 | reit | JMP Securities | Market Outperform → Market Outperform | $18 |
| 2024-11-27 | init | Raymond James | — → Outperform | $23 |
| 2024-11-18 | init | JMP Securities | — → Market Outperform | $18 |
- New name, same ticker: enGene ties rebrand to a 2027 transition - Stock Titan ue, 07 Apr 2026 07
- enGene Holdings (ENGN) Stock: Overpriced? (At Lows) 2026-04-18 - Attention Driven Stocks - Cổng thông tin điện tử tỉnh Tây Ninh Sat, 18 Apr 2026 05
- enGene Rebrands as enGene Therapeutics Ahead of Potential 2027 Commercial Launch - TipRanks ue, 07 Apr 2026 07
- enGene (NASDAQ:ENGN) Shares Up 5.2% - Here's Why - MarketBeat ue, 07 Apr 2026 07
- enGene stock rises after detalimogene shows improved response rate in bladder cancer - Investing.com ue, 11 Nov 2025 08
- enGene Holdings: Key Catalysts Incoming For 2026 (NASDAQ:ENGN) - Seeking Alpha hu, 12 Mar 2026 07
- ENGN Stock Soars On Hopeful Data From Bladder Cancer Study - Stocktwits ue, 11 Nov 2025 08
- WBB Securities initiates coverage of Engene Therapeutics (ENGN) with buy recommendation - MSN Fri, 24 Apr 2026 21
- ENGN Options Chain — NASDAQ:ENGN - TradingView ue, 14 Apr 2026 06
- Genetic medicines firm enGene to speak at four major healthcare investor events - Stock Titan Fri, 20 Feb 2026 13
- enGene Holdings: Still A Buy After A Massive Surge (ENGN) - Seeking Alpha Wed, 12 Nov 2025 08
- WBB Securities Initiates Coverage on enGene (NASDAQ:ENGN) - MarketBeat Mon, 13 Apr 2026 07
- Experimental bladder cancer treatment from enGene aims for FDA review in 2026 - Stock Titan Mon, 09 Mar 2026 07
- Detalimogene program drives enGene (ENGN) shift to Therapeutics focus - Stock Titan hu, 09 Apr 2026 07
- Biotech enGene secures $125M to advance bladder cancer treatment detalimogene - Stock Titan ue, 20 Jan 2026 08
Insider Transactions
Financials
| Line Item | Trend | 2025-10-31 | 2024-10-31 | 2023-10-31 | 2022-10-31 |
|---|---|---|---|---|---|
| Total Revenue |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Operating Revenue |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Operating Expense |
|
123.17
+97.71%
|
62.30
+139.05%
|
26.06
+34.14%
|
19.43
|
| Research And Development |
|
94.48
+146.59%
|
38.31
+132.80%
|
16.46
+6.41%
|
15.47
|
| Selling General And Administration |
|
28.68
+19.61%
|
23.98
+183.14%
|
8.47
+159.82%
|
3.26
|
| General And Administrative Expense |
|
28.68
+19.61%
|
23.98
+183.14%
|
8.47
+159.82%
|
3.26
|
| Salaries And Wages |
|
17.21
+43.08%
|
12.03
+151.69%
|
4.78
+132.60%
|
2.06
|
| Other Gand A |
|
11.47
-4.02%
|
11.95
+223.88%
|
3.69
+206.22%
|
1.21
|
| Other Operating Expenses |
|
—
|
1.88
+65.99%
|
1.13
+61.71%
|
0.70
|
| Total Expenses |
|
123.17
+97.71%
|
62.30
+139.05%
|
26.06
+34.14%
|
19.43
|
| Operating Income |
|
-123.17
-97.71%
|
-62.30
-139.05%
|
-26.06
-34.14%
|
-19.43
|
| Total Operating Income As Reported |
|
-123.17
-97.71%
|
-62.30
-139.05%
|
-26.06
-34.14%
|
-19.43
|
| EBITDA |
|
-113.80
-118.68%
|
-52.04
+45.09%
|
-94.77
-316.05%
|
-22.78
|
| Normalized EBITDA |
|
-113.80
-120.22%
|
-51.67
+36.29%
|
-81.11
-311.26%
|
-19.72
|
| Reconciled Depreciation |
|
0.51
+57.59%
|
0.32
+84.57%
|
0.17
-26.47%
|
0.24
|
| EBIT |
|
-114.31
-118.30%
|
-52.36
+44.85%
|
-94.95
-312.51%
|
-23.02
|
| Total Unusual Items |
|
0.00
+100.00%
|
-0.37
+97.32%
|
-13.66
-346.94%
|
-3.06
|
| Total Unusual Items Excluding Goodwill |
|
0.00
+100.00%
|
-0.37
+97.32%
|
-13.66
-346.94%
|
-3.06
|
| Special Income Charges |
|
0.00
+100.00%
|
-0.37
+88.16%
|
-3.09
|
0.00
|
| Other Special Charges |
|
—
|
0.37
-88.16%
|
3.09
|
—
|
| Net Income |
|
-117.30
-112.73%
|
-55.14
+44.81%
|
-99.92
-308.46%
|
-24.46
|
| Pretax Income |
|
-117.30
-112.65%
|
-55.16
+44.78%
|
-99.90
-308.76%
|
-24.44
|
| Net Non Operating Interest Income Expense |
|
6.43
-15.54%
|
7.62
+298.51%
|
-3.84
-196.45%
|
-1.29
|
| Interest Expense Non Operating |
|
2.99
+7.01%
|
2.80
-43.51%
|
4.95
+248.07%
|
1.42
|
| Net Interest Income |
|
6.43
-15.54%
|
7.62
+298.51%
|
-3.84
-196.45%
|
-1.29
|
| Interest Expense |
|
2.99
+7.01%
|
2.80
-43.51%
|
4.95
+248.07%
|
1.42
|
| Interest Income Non Operating |
|
9.43
-9.48%
|
10.41
+832.23%
|
1.12
+765.89%
|
0.13
|
| Interest Income |
|
9.43
-9.48%
|
10.41
+832.23%
|
1.12
+765.89%
|
0.13
|
| Other Income Expense |
|
-0.57
-18.79%
|
-0.48
+99.32%
|
-70.00
-1782.33%
|
-3.72
|
| Other Non Operating Income Expenses |
|
-0.57
-403.54%
|
-0.11
+99.80%
|
-56.34
-8410.73%
|
-0.66
|
| Gain On Sale Of Security |
|
—
|
—
|
-10.57
-245.83%
|
-3.06
|
| Tax Provision |
|
0.00
+100.00%
|
-0.02
-211.76%
|
0.02
-22.73%
|
0.02
|
| Tax Rate For Calcs |
|
0.00
-100.00%
|
0.00
-99.93%
|
0.00
+52.61%
|
0.00
|
| Tax Effect Of Unusual Items |
|
0.00
+100.00%
|
-0.00
+100.00%
|
-5.47
-582.09%
|
-0.80
|
| Net Income Including Noncontrolling Interests |
|
-117.30
-112.73%
|
-55.14
+44.81%
|
-99.92
-308.46%
|
-24.46
|
| Net Income From Continuing Operation Net Minority Interest |
|
-117.30
-112.73%
|
-55.14
+44.81%
|
-99.92
-308.46%
|
-24.46
|
| Net Income From Continuing And Discontinued Operation |
|
-117.30
-112.73%
|
-55.14
+44.81%
|
-99.92
-308.46%
|
-24.46
|
| Net Income Continuous Operations |
|
-117.30
-112.73%
|
-55.14
+44.81%
|
-99.92
-308.46%
|
-24.46
|
| Normalized Income |
|
-117.30
-114.15%
|
-54.78
+40.28%
|
-91.72
-313.03%
|
-22.21
|
| Net Income Common Stockholders |
|
-117.30
-112.73%
|
-55.14
+47.35%
|
-104.74
-260.87%
|
-29.02
|
| Otherunder Preferred Stock Dividend |
|
—
|
—
|
—
|
0.00
|
| Diluted EPS |
|
-2.29
-56.85%
|
-1.46
+67.66%
|
-4.52
-260.87%
|
-1.25
|
| Basic EPS |
|
-2.29
-56.85%
|
-1.46
+67.66%
|
-4.52
-260.87%
|
-1.25
|
| Basic Average Shares |
|
51.12
+35.30%
|
37.78
+62.87%
|
23.20
+0.00%
|
23.20
|
| Diluted Average Shares |
|
51.12
+35.30%
|
37.78
+62.87%
|
23.20
+0.00%
|
23.20
|
| Diluted NI Availto Com Stockholders |
|
-117.30
-112.73%
|
-55.14
+47.35%
|
-104.74
-260.87%
|
-29.02
|
| Preferred Stock Dividends |
|
—
|
—
|
4.82
+5.70%
|
4.56
|
| Line Item | Trend | 2025-10-31 | 2024-10-31 | 2023-10-31 | 2022-10-31 |
|---|---|---|---|---|---|
| Total Assets |
|
221.47
-28.83%
|
311.17
+257.84%
|
86.96
+263.71%
|
23.91
|
| Current Assets |
|
201.39
-18.58%
|
247.36
+189.52%
|
85.44
+278.34%
|
22.58
|
| Cash Cash Equivalents And Short Term Investments |
|
193.74
-18.71%
|
238.33
+192.36%
|
81.52
+298.95%
|
20.43
|
| Cash And Cash Equivalents |
|
50.15
-71.01%
|
173.00
+112.22%
|
81.52
+298.95%
|
20.43
|
| Other Short Term Investments |
|
143.58
+119.79%
|
65.33
|
0.00
|
—
|
| Receivables |
|
0.93
+179.22%
|
0.33
-85.83%
|
2.34
+75.37%
|
1.34
|
| Taxes Receivable |
|
0.93
+179.22%
|
0.33
-85.83%
|
2.34
+75.37%
|
1.34
|
| Restricted Cash |
|
0.08
+9.72%
|
0.07
-5.26%
|
0.08
+2.70%
|
0.07
|
| Other Current Assets |
|
6.65
-22.92%
|
8.63
+475.07%
|
1.50
+102.98%
|
0.74
|
| Total Non Current Assets |
|
20.08
-68.54%
|
63.81
+4100.86%
|
1.52
+14.56%
|
1.33
|
| Net PPE |
|
10.19
+250.27%
|
2.91
+394.06%
|
0.59
+52.20%
|
0.39
|
| Gross PPE |
|
12.30
+172.04%
|
4.52
+95.16%
|
2.32
+19.38%
|
1.94
|
| Accumulated Depreciation |
|
-2.10
-30.62%
|
-1.61
+6.77%
|
-1.73
-11.20%
|
-1.55
|
| Properties |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Buildings And Improvements |
|
7.72
+343.19%
|
1.74
|
0.00
|
0.00
|
| Machinery Furniture Equipment |
|
1.18
+239.26%
|
0.35
-14.46%
|
0.41
+17.92%
|
0.35
|
| Other Properties |
|
3.13
+43.04%
|
2.19
+23.16%
|
1.78
+20.86%
|
1.47
|
| Leases |
|
0.26
+9.62%
|
0.24
+85.27%
|
0.13
+5.74%
|
0.12
|
| Investments And Advances |
|
8.52
-85.68%
|
59.53
|
0.00
|
—
|
| Other Non Current Assets |
|
1.36
-0.87%
|
1.37
+47.74%
|
0.93
-0.96%
|
0.94
|
| Total Liabilities Net Minority Interest |
|
53.76
+39.41%
|
38.56
+166.43%
|
14.47
-69.47%
|
47.41
|
| Current Liabilities |
|
31.98
+118.12%
|
14.66
+178.89%
|
5.26
+3.00%
|
5.10
|
| Payables And Accrued Expenses |
|
17.33
+76.17%
|
9.84
+161.12%
|
3.77
+19.13%
|
3.16
|
| Payables |
|
6.71
+375.34%
|
1.41
+18.08%
|
1.20
+60.40%
|
0.74
|
| Accounts Payable |
|
6.69
+373.99%
|
1.41
+22.06%
|
1.16
+59.89%
|
0.72
|
| Current Accrued Expenses |
|
10.63
+26.08%
|
8.43
+227.56%
|
2.57
+6.41%
|
2.42
|
| Pensionand Other Post Retirement Benefit Plans Current |
|
4.05
+16.63%
|
3.48
+326.90%
|
0.81
+20.41%
|
0.68
|
| Total Tax Payable |
|
0.02
|
0.00
-100.00%
|
0.04
+77.27%
|
0.02
|
| Income Tax Payable |
|
0.02
|
0.00
-100.00%
|
0.04
+77.27%
|
0.02
|
| Current Debt And Capital Lease Obligation |
|
10.02
+792.69%
|
1.12
+99.64%
|
0.56
-55.57%
|
1.26
|
| Current Debt |
|
8.00
+1044.78%
|
0.70
+24.38%
|
0.56
-55.57%
|
1.26
|
| Other Current Borrowings |
|
8.00
+1044.78%
|
0.70
+24.38%
|
0.56
-55.57%
|
1.26
|
| Current Capital Lease Obligation |
|
2.01
+376.12%
|
0.42
|
0.00
|
0.00
|
| Other Current Liabilities |
|
0.58
+156.44%
|
0.23
+99.12%
|
0.11
|
—
|
| Total Non Current Liabilities Net Minority Interest |
|
21.78
-8.87%
|
23.90
+159.33%
|
9.22
-78.21%
|
42.30
|
| Long Term Debt And Capital Lease Obligation |
|
21.78
-8.87%
|
23.90
+159.33%
|
9.22
-70.12%
|
30.84
|
| Long Term Debt |
|
15.32
-31.81%
|
22.47
+143.85%
|
9.22
-70.12%
|
30.84
|
| Long Term Capital Lease Obligation |
|
6.46
+352.35%
|
1.43
|
0.00
|
—
|
| Preferred Securities Outside Stock Equity |
|
—
|
—
|
0.00
-100.00%
|
53.12
|
| Stockholders Equity |
|
167.71
-38.48%
|
272.61
+276.09%
|
72.49
+408.50%
|
-23.50
|
| Common Stock Equity |
|
167.71
-38.48%
|
272.61
+276.09%
|
72.49
+194.61%
|
-76.61
|
| Capital Stock |
|
513.28
+0.68%
|
509.81
+96.56%
|
259.37
+273.16%
|
69.51
|
| Common Stock |
|
513.28
+0.68%
|
509.81
+96.56%
|
259.37
+1482.51%
|
16.39
|
| Preferred Stock |
|
—
|
—
|
0.00
-100.00%
|
53.12
|
| Share Issued |
|
52.02
+2.04%
|
50.98
+119.75%
|
23.20
+0.00%
|
23.20
|
| Ordinary Shares Number |
|
52.02
+2.04%
|
50.98
+119.75%
|
23.20
+0.00%
|
23.20
|
| Additional Paid In Capital |
|
27.35
+44.32%
|
18.95
+38.15%
|
13.72
+78.54%
|
7.68
|
| Retained Earnings |
|
-372.03
-46.05%
|
-254.73
-27.63%
|
-199.59
-100.25%
|
-99.67
|
| Gains Losses Not Affecting Retained Earnings |
|
-0.89
+37.42%
|
-1.42
-39.67%
|
-1.02
+0.00%
|
-1.02
|
| Other Equity Adjustments |
|
-0.89
+37.42%
|
-1.42
-39.67%
|
-1.02
+0.00%
|
-1.02
|
| Total Equity Gross Minority Interest |
|
167.71
-38.48%
|
272.61
+276.09%
|
72.49
+408.50%
|
-23.50
|
| Total Capitalization |
|
183.03
-37.97%
|
295.08
+261.17%
|
81.70
+1011.74%
|
7.35
|
| Working Capital |
|
169.41
-27.20%
|
232.70
+190.21%
|
80.18
+358.74%
|
17.48
|
| Invested Capital |
|
191.04
-35.41%
|
295.78
+259.55%
|
82.26
+284.85%
|
-44.50
|
| Total Debt |
|
31.80
+27.07%
|
25.02
+155.90%
|
9.78
-69.55%
|
32.11
|
| Net Debt |
|
—
|
—
|
—
|
11.68
|
| Capital Lease Obligations |
|
8.47
+357.78%
|
1.85
|
0.00
|
0.00
|
| Net Tangible Assets |
|
167.71
-38.48%
|
272.61
+276.09%
|
72.49
+408.50%
|
-23.50
|
| Tangible Book Value |
|
167.71
-38.48%
|
272.61
+276.09%
|
72.49
+194.61%
|
-76.61
|
| Available For Sale Securities |
|
8.52
-85.68%
|
59.53
|
—
|
—
|
| Derivative Product Liabilities |
|
—
|
—
|
0.00
-100.00%
|
11.46
|
| Investmentin Financial Assets |
|
8.52
-85.68%
|
59.53
|
0.00
|
—
|
| Preferred Stock Equity |
|
—
|
—
|
—
|
53.12
|
| Line Item | Trend | 2025-10-31 | 2024-10-31 | 2023-10-31 | 2022-10-31 |
|---|---|---|---|---|---|
| Operating Cash Flow |
|
-99.24
-105.54%
|
-48.28
-95.13%
|
-24.74
-40.65%
|
-17.59
|
| Cash Flow From Continuing Operating Activities |
|
-99.24
-105.54%
|
-48.28
-95.13%
|
-24.74
-40.65%
|
-17.59
|
| Net Income From Continuing Operations |
|
-117.30
-112.73%
|
-55.14
+44.81%
|
-99.92
-308.46%
|
-24.46
|
| Depreciation Amortization Depletion |
|
0.51
+57.59%
|
0.32
+84.57%
|
0.17
-26.47%
|
0.24
|
| Depreciation |
|
0.51
+57.59%
|
0.32
+84.57%
|
0.17
-26.47%
|
0.24
|
| Depreciation And Amortization |
|
0.51
+57.59%
|
0.32
+84.57%
|
0.17
-26.47%
|
0.24
|
| Other Non Cash Items |
|
1.23
+27.14%
|
0.97
-43.07%
|
1.70
+166.35%
|
0.64
|
| Stock Based Compensation |
|
9.65
+81.18%
|
5.32
+54.32%
|
3.45
+2874.14%
|
0.12
|
| Operating Gains Losses |
|
0.00
-99.21%
|
0.38
-97.30%
|
14.15
+282.18%
|
3.70
|
| Gain Loss On Investment Securities |
|
—
|
—
|
10.57
+245.83%
|
3.06
|
| Unrealized Gain Loss On Investment Securities |
|
—
|
0.00
-100.00%
|
56.21
|
0.00
|
| Net Foreign Currency Exchange Gain Loss |
|
0.00
+150.00%
|
-0.01
-101.23%
|
0.49
-24.30%
|
0.65
|
| Gain Loss On Sale Of PPE |
|
0.00
-100.00%
|
0.02
|
0.00
|
—
|
| Change In Working Capital |
|
9.74
+10152.63%
|
0.10
+118.38%
|
-0.52
-123.78%
|
2.17
|
| Change In Receivables |
|
-0.59
-129.59%
|
2.01
+299.70%
|
-1.01
-804.20%
|
0.14
|
| Change In Prepaid Assets |
|
1.99
+126.29%
|
-7.57
-907.46%
|
-0.75
-564.60%
|
-0.11
|
| Change In Payables And Accrued Expense |
|
8.07
+41.64%
|
5.70
+359.23%
|
1.24
-42.12%
|
2.14
|
| Change In Accrued Expense |
|
3.13
-40.10%
|
5.22
+501.96%
|
0.87
-62.92%
|
2.34
|
| Change In Payable |
|
4.94
+942.62%
|
0.47
+27.08%
|
0.37
+289.34%
|
-0.20
|
| Change In Account Payable |
|
4.94
+942.62%
|
0.47
+27.08%
|
0.37
+289.34%
|
-0.20
|
| Change In Other Current Liabilities |
|
0.27
+659.18%
|
-0.05
|
0.00
|
—
|
| Investing Cash Flow |
|
-25.14
+80.04%
|
-125.95
-39507.86%
|
-0.32
-107.84%
|
-0.15
|
| Cash Flow From Continuing Investing Activities |
|
-25.14
+80.04%
|
-125.95
-39507.86%
|
-0.32
-107.84%
|
-0.15
|
| Net PPE Purchase And Sale |
|
-1.49
-60.54%
|
-0.93
-190.88%
|
-0.32
-107.84%
|
-0.15
|
| Purchase Of PPE |
|
-1.49
-60.54%
|
-0.93
-190.88%
|
-0.32
-107.84%
|
-0.15
|
| Sale Of PPE |
|
—
|
—
|
—
|
0.00
|
| Capital Expenditure |
|
-1.49
-60.54%
|
-0.93
-190.88%
|
-0.32
-107.84%
|
-0.15
|
| Net Investment Purchase And Sale |
|
-23.65
+81.08%
|
-125.03
|
0.00
|
—
|
| Purchase Of Investment |
|
-160.84
-28.65%
|
-125.03
|
0.00
|
—
|
| Sale Of Investment |
|
137.19
|
0.00
|
—
|
—
|
| Financing Cash Flow |
|
1.52
-99.43%
|
265.72
+208.44%
|
86.15
+208.03%
|
27.97
|
| Cash Flow From Continuing Financing Activities |
|
1.52
-99.43%
|
265.72
+208.44%
|
86.15
+208.03%
|
27.97
|
| Net Issuance Payments Of Debt |
|
-0.70
-105.35%
|
13.05
-60.76%
|
33.27
+17.19%
|
28.39
|
| Issuance Of Debt |
|
0.00
-100.00%
|
22.50
-40.79%
|
38.00
+29.25%
|
29.40
|
| Repayment Of Debt |
|
-0.70
+92.60%
|
-9.45
-99.64%
|
-4.73
-368.42%
|
-1.01
|
| Long Term Debt Issuance |
|
0.00
-100.00%
|
22.50
-40.79%
|
38.00
+29.25%
|
29.40
|
| Long Term Debt Payments |
|
-0.70
+92.60%
|
-9.45
-99.64%
|
-4.73
-368.42%
|
-1.01
|
| Net Long Term Debt Issuance |
|
-0.70
-105.35%
|
13.05
-60.76%
|
33.27
+17.19%
|
28.39
|
| Net Common Stock Issuance |
|
0.00
-100.00%
|
260.15
+357.27%
|
56.89
|
0.00
|
| Proceeds From Stock Option Exercised |
|
2.22
-63.53%
|
6.10
+13754.55%
|
0.04
+266.67%
|
0.01
|
| Net Other Financing Charges |
|
—
|
-13.58
-234.75%
|
-4.06
-832.87%
|
-0.43
|
| Changes In Cash |
|
-122.85
-234.29%
|
91.48
+49.76%
|
61.09
+497.59%
|
10.22
|
| Effect Of Exchange Rate Changes |
|
0.00
+0.00%
|
0.00
+0.00%
|
0.00
+100.12%
|
-0.81
|
| Beginning Cash Position |
|
173.00
+112.22%
|
81.52
+298.95%
|
20.43
+85.48%
|
11.02
|
| End Cash Position |
|
50.15
-71.01%
|
173.00
+112.22%
|
81.52
+298.95%
|
20.43
|
| Free Cash Flow |
|
-100.72
-104.70%
|
-49.21
-96.34%
|
-25.06
-41.23%
|
-17.75
|
| Interest Paid Supplemental Data |
|
2.29
+18.91%
|
1.93
+37.70%
|
1.40
+127.32%
|
0.61
|
| Amortization Of Securities |
|
-3.07
-1221.98%
|
-0.23
|
0.00
|
—
|
| Common Stock Issuance |
|
0.00
-100.00%
|
260.15
+357.27%
|
56.89
|
0.00
|
| Issuance Of Capital Stock |
|
0.00
-100.00%
|
260.15
+357.27%
|
56.89
|
0.00
|
| Net Preferred Stock Issuance |
|
—
|
—
|
—
|
0.00
|
| Preferred Stock Issuance |
|
—
|
—
|
—
|
0.00
|
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
- 8-K2026-04-09 View
- 8-K2026-03-09 View
- 10-Q2026-03-09 View
- 8-K2026-03-09 View
- 42026-02-03 View
- 42026-02-03 View
- 42026-02-03 View
- 42026-02-03 View
- 42026-02-03 View
- 42026-02-03 View
- 42026-02-03 View
- 42026-02-03 View
- 8-K2026-01-21 View
- 8-K2026-01-21 View
- 10-K2025-12-22 View
- 8-K2025-12-22 View
- 8-K2025-11-14 View
- 8-K2025-11-12 View
- 8-K2025-10-02 View
- 42025-10-01 View
Trades
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|
Posts
| Published | Title | Author | Category |
|---|